🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

NGL Fine-Chem Limited NGLFINE NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.nglfinechem.com
Company Profile ↓
₹2,623.40
+96.20% 1Y
Mkt Cap₹1,620.74 Cr
P/E28.33
P/B5.49
Div. Yield0.06%
52W High₹3,455.72
52W Low₹1,278.03
Book Value₹532.92
EPS (TTM)₹92.59

Company Overview

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxacin, maropitant citrate monohydrate, nitroscanate, nitroxynil, oclacitinib maleate, oxfendazole, parvaquone, permethrin, phenazone, ponazuril, praziquantel, ractopamine HCL, rafoxanide, ricobendazole, r-praziquantel, sarolaner, s-methoprene, toldimfos sodium, toltrazuril, triclabendazole, xylazine base, xylazine HCl, and zilpaterol. It also provides anthelmintics, antiprotozoals, ectoparasiticides, phosphorus supplements, coccidiostats, and non-steroidal anti-inflammatory drugs. In addition, the company offers atovaquone, nitazoxanide, and praziquantel for anti malarial, anti diarrheal, and anthelmintic therapeutic categories. Further, it provides specialty chemicals, such as meglumine, n-ethyl-d-glucamine, n-octyl-d-glucamine, 1,4,7-trimethyl-1,4,7-triazonane, and Mn-MeTACN. It serves companies engages in manufacturing custom pharmaceuticals. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 17.2%.

Consistent Profit Growth

Net profit has compounded at 32.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 21.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 28.3, below the sector median of 36.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.37.

Recent Developments

  • Mar 2026 Revenue of ₹494.13 Cr (+36.1% YoY); net profit ₹48.13 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +33.6%, earnings +99.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 21.8%, profit CAGR 32.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:21.78%
1 Year:33.60%

Compounded Profit Growth

5 Years:32.91%
1 Year:99.10%

Stock Price Performance

1 Year:+96.20%
6 Months:+17.40%
3 Months:-19.39%
1 Month:-3.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 62% of range
₹1,278.03 ₹3,455.72
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)34.82 · Neutral
Price Performance
1M-3.96%
3M-19.39%
6M+17.40%
1Y+96.20%
Valuation vs Sector

P/E of 28.33 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 21.8% over 5 years.
  • Profit CAGR of 32.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
28.33
Industry PE
36.43
Forward P/E est.
14.23
PEG Ratio
-
Book Value
₹532.92
Price to Book
5.49
P/S
3.37
EV/EBITDA
23.62
Dividend Yield
0.06%

Growth (CAGR)

Revenue 5Y
21.78%
Profit 5Y
32.91%
Revenue (YoY)
33.60%
Earnings (YoY)
99.10%

Profitability & Returns

ROCE
17.15%
ROE
14.62%
ROA
8.82%
Profit Margin
10.69%
Op Margin
12.96%
Gross Margin
50.86%
EPS (Latest Qtr)
₹21.83
EPS (TTM)
₹92.59

Balance Sheet & Liquidity

Debt/Equity
0.37
Quick Ratio
1.37
Current Ratio
1.84
Debt
₹122.58 Cr
Total Assets
₹545.50 Cr
Current Assets
₹276.39 Cr
Working Capital
₹126.38 Cr

Ownership

Promoter Holding
72.49%
Chg in Prom Hold
-0.07%
FII / Inst Holding
0.00%
Chg in FII Hold
-0.03%

Financial Snapshot

Enterprise Value
₹1,620.74 Cr
Total Revenue (TTM)
₹535.93 Cr
EBITDA
₹85.29 Cr
Free Cash Flow
₹-46.53 Cr
Operating Cash Flow
₹43.32 Cr
Shares Outstanding
₹61.78 L
Gross Margin
50.86%
Payout Ratio
1.89%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NGLFINE NGL Fine-Chem Limited NSEPHARMA 2,623.40 28.33 ₹1,620.74 Cr 0.06% 17.15% 14.62% 21.78% 32.91%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 75.00 Cr71.00 Cr80.00 Cr88.00 Cr100.00 Cr91.00 Cr93.00 Cr89.00 Cr94.97 Cr104.19 Cr120.26 Cr127.51 Cr149.23 Cr
Cost of Revenue --------47.80 Cr51.89 Cr57.27 Cr59.51 Cr70.90 Cr
Gross Profit --------47.17 Cr52.29 Cr62.99 Cr68.00 Cr78.33 Cr
Operating Expenses 61.00 Cr61.00 Cr66.00 Cr74.00 Cr84.00 Cr81.00 Cr82.00 Cr84.00 Cr44.17 Cr45.59 Cr50.92 Cr50.87 Cr61.97 Cr
Operating Income 11.00 Cr7.00 Cr11.00 Cr11.00 Cr13.00 Cr6.00 Cr9.00 Cr2.00 Cr3.00 Cr6.71 Cr12.07 Cr17.13 Cr16.36 Cr
EBITDA 14.00 Cr10.00 Cr14.00 Cr14.00 Cr16.00 Cr9.00 Cr12.00 Cr5.00 Cr5.35 Cr17.33 Cr19.21 Cr26.93 Cr23.87 Cr
Interest Expense 00000001.00 Cr97.36 L1.22 Cr1.16 Cr1.07 Cr1.01 Cr
Pretax Income 12.00 Cr10.00 Cr14.00 Cr14.00 Cr16.00 Cr12.00 Cr13.00 Cr1.00 Cr1.06 Cr11.84 Cr12.96 Cr20.67 Cr17.81 Cr
Tax Provision 2.76 Cr1.60 Cr3.50 Cr4.20 Cr3.68 Cr2.64 Cr3.38 Cr-1.00 L51.65 L2.60 Cr3.34 Cr4.98 Cr4.33 Cr
Net Income 9.00 Cr9.00 Cr10.00 Cr10.00 Cr12.00 Cr9.00 Cr10.00 Cr1.00 Cr54.36 L9.24 Cr9.63 Cr15.69 Cr13.49 Cr
Diluted EPS 15.0913.7716.9616.2419.9414.9215.882.070.8814.9615.5825.4021.83

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 153.00 Cr152.00 Cr258.00 Cr-273.57 Cr333.71 Cr363.03 Cr494.13 Cr
Cost of Revenue ----140.32 Cr158.69 Cr182.41 Cr239.49 Cr
Gross Profit ----133.25 Cr175.03 Cr180.62 Cr254.64 Cr
Operating Expenses 121.00 Cr130.00 Cr178.00 Cr-109.59 Cr132.93 Cr157.97 Cr193.95 Cr
Operating Income 26.00 Cr14.00 Cr72.00 Cr-23.67 Cr42.10 Cr22.65 Cr60.69 Cr
EBITDA 32.00 Cr22.00 Cr80.00 Cr-39.85 Cr67.40 Cr42.50 Cr87.42 Cr
Interest Expense 3.00 Cr3.00 Cr2.00 Cr-1.20 Cr1.34 Cr2.33 Cr4.47 Cr
Pretax Income 28.00 Cr12.00 Cr78.00 Cr-27.36 Cr54.42 Cr27.71 Cr63.37 Cr
Tax Provision 7.56 Cr3.72 Cr21.06 Cr-6.87 Cr13.10 Cr6.59 Cr15.24 Cr
Net Income 20.00 Cr8.00 Cr57.00 Cr-20.50 Cr41.32 Cr21.12 Cr48.13 Cr
Diluted EPS 32.5813.5091.8180.7733.1866.8834.19-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 142.00 Cr154.00 Cr207.00 Cr-287.08 Cr355.54 Cr434.68 Cr545.50 Cr
Current Assets ----162.66 Cr212.67 Cr233.88 Cr276.39 Cr
Cash & Equivalents ----7.83 Cr39.52 L38.33 L2.63 Cr
Inventory ----26.99 Cr43.30 Cr51.27 Cr70.28 Cr
Receivables ----65.87 Cr89.62 Cr82.84 Cr130.88 Cr
Total Liabilities ----64.53 Cr92.90 Cr152.25 Cr216.26 Cr
Current Liabilities ----58.29 Cr86.59 Cr118.42 Cr150.01 Cr
Long Term Debt ----2.07 Cr74.48 L25.34 Cr56.40 Cr
Total Debt 27.00 Cr28.00 Cr16.00 Cr-32.50 Cr34.00 Cr77.66 Cr122.58 Cr
Total Equity 92.00 Cr99.00 Cr154.00 Cr-222.55 Cr262.63 Cr282.43 Cr329.24 Cr
Shares Outstanding ----61.78 L61.78 L61.78 L61.78 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 9.00 Cr20.00 Cr27.00 Cr-35.29 Cr20.47 Cr32.35 Cr43.32 Cr
Investing Cash Flow -10.00 Cr-20.00 Cr-25.00 Cr--27.02 Cr-26.82 Cr-69.68 Cr-70.59 Cr
Financing Cash Flow 0-1.00 Cr-1.00 Cr--1.08 Cr-1.08 Cr37.47 Cr29.55 Cr
Capital Expenditure -15.00 Cr-14.00 Cr-17.00 Cr--31.41 Cr-28.52 Cr-74.29 Cr-89.85 Cr
Free Cash Flow -6.00 Cr6.00 Cr10.00 Cr-3.88 Cr-8.06 Cr-41.94 Cr-46.53 Cr
Net Change in Cash -1.00 Cr-02.00 Cr-7.18 Cr-7.43 Cr13.94 L2.27 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----48.7%52.4%49.8%51.5%
Operating Margin % 17.0%9.2%27.9%-8.7%12.6%6.2%12.3%
Net Margin % 13.1%5.3%22.1%-7.5%12.4%5.8%9.7%
ROE % 21.7%8.1%37.0%-9.2%15.7%7.5%14.6%
ROCE % ----10.3%15.7%7.2%15.3%

Shareholding Pattern

Insiders
72.49%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NGLFINE

Google News hu, 22 Oct 2026

NGL Fine-Chem Limited (NGLFINE.NS) stock price, news, quote and history - Yahoo Finance Australia

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE9jd3RIVm81bGFRcVFJNm9mZERqMWNCSW1vckZ3NHU1YzVneUM3X3FqcUNVYk9BaFVEaFdLV2s0V1A2d09QRW8zTkNrM1E3dzRzTWt1X0ZvS0VPcndkVHp3ZkcyekdLMGpnM3c?oc=5" target="_blank">NGL Fine-Chem Limited (N…

Google News Sat, 17 Oct 2026

ETFs Investing in NGL Fine-Chem Ltd. Stocks - TradingView

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTFBEY3pLZFQtbGFpdW5PMWtvblFMeTZkT0pETnhIcHlicUJIXzFtalpCcWtYM2s1SmFPMWZUaFNwYlRlenZHLXhISDNjaU1NSEdLc1lMRmZUc0pacVhwMVVIWlNjZw?oc=5" target="_blank">ETFs Investing in NGL Fine-Chem L…

Google News ue, 13 Oct 2026

NGL Fine-Chem (NGLFINE) Share/Stock Price Live, NSE - TechGraph

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5rTFlEV01IYnRwb3JlcVhRQnZtR2tRSGdLN21ZckplZ3RWTzlsYWw4ZzJ4UGFNdGxha1BoY1pheVJfZUFxWmx3RFBjWTBvNDZINTROZFhCRzctUGJ1OE5KRg?oc=5" target="_blank">NGL Fine-Chem (NGLFINE) Share/Stock P…

Google News Wed, 23 Sep 2026

Is Now The Time To Put NGL Fine-Chem (NSE:NGLFINE) On Your Watchlist? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOd3ljLTBGdjR5dXJodVlwUGF5S0pBWENZSDZhNVVvVm1KZU9MSlRYX2pGc3B1a0RpQ1h3X1hFc2Q1VE1mWEtlemJaYldOTzRSaXowQnNtTFNwUVV5QUszTEhJQXpoNFN0aUJLUFhYTzdyb2xNUzRhVDRHT0RqZjJYQzI4R0ZZQ1VGVEVtN1…

Google News Fri, 09 Oct 2026

NGL Fine-Chem (NGLFINE.NS) Slips 1.43% to ₹2,955.9 as Stock Consolidates Below ₹3,100 - NHNL Ratio - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa3pYR3dRYzZFNjY0MmJ5Y19VRmlQTUJQQl9HRV9jRW5PZElaU040QmdXTmJVSEtkUUhDUjlwQU1BeTduQ1NUcmJDeWdpc1NGUE15emdxV0NPNTdkLXREZW1ZUEgxRG1TSTZoYk9LN2xOWThFU2lQWHd4TjZCLUxVWFhMQjU1a0J0RFE2Nz…

Google News Mon, 17 Aug 2026

NGL Fine Chem Q1 Results: Net profit up 99% YoY to ₹18.40 crore - scanx.trade

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOdEdGQ1VackUtcEwzaktDVFA5NkZ1QkMyMGR5cng3SjFBTEJ6NWUtVFlLZDR6cGREZWpIYkl1M2JWaTdpRmJXVHZXalUyeXRvWlBGVEc1YVpMNGwwQXJsZVF0ZF9TSzZNTy1qWFBSMjFCVk1lTGVLYWkzT05hZ24wczA1ZFl0U1EwaENkOU…

NGLFINE — Frequently Asked Questions

What is the current share price of NGL Fine-Chem Limited (NGLFINE)?

As of 2026-10-23 04:58 IST, NGL Fine-Chem Limited (NGLFINE) trades at ₹2,623.40 on NSE. Its 52-week range is ₹1,278.03 to ₹3,455.72.

What is the market capitalisation of NGLFINE?

NGL Fine-Chem Limited (NGLFINE) has a market capitalisation of ₹1,620.74 Cr on NSE.

What is the P/E ratio of NGLFINE?

NGLFINE trades at a trailing price-to-earnings (P/E) ratio of 28.33. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.49.

Does NGLFINE pay a dividend?

NGL Fine-Chem Limited (NGLFINE) currently offers a dividend yield of 0.06%.

What is the return on equity (ROE) of NGLFINE?

NGLFINE has a return on equity (ROE) of 14.62%. Its return on capital employed (ROCE) is 17.15%.

Is NGLFINE a good stock to buy?

This page provides a data-driven analysis of NGL Fine-Chem Limited (NGLFINE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space